Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890350) titled 'Study of CM512 Injection in Patients With Perennial Allergic Rhinitis on Background Therapy' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Beijing Keymed Biosciences Co., Ltd.
Condition:
Perennial Allergic Rhinitis (PAR)
Intervention:
Biological: CM512
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 2026
Target Sample Size: 200
Countries of Recruitment:
China
To know more...